Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
The Lancet. Haematology|June 15, 2026
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trialNicolò Peccatori, Franco Locatelli, Anneke C J Ammerlaan, et al.
Blood|December 25, 2015
Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescentsMarcin W Wlodarski, Shinsuke Hirabayashi, Victor Pastor, et al.
Trials|June 19, 2026
CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortiumGertjan J L Kaspers, Merlijn van Hamel, Jonas Abrahamsson, et al.
The New England Journal of Medicine|February 1, 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L Maude, Theodore W Laetsch, Jochen Buechner, et al.
Leukemia|June 20, 2020
Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiencyEmilia J Kozyra, Victor B Pastor, Stylianos Lefkopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study GroupRomy E van Weelderen, Kim Klein, Christine J Harrison, et al.
Nature Communications|December 21, 2017
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemiaDaniel B Lipka, Tania Witte, Reka Toth, et al.
Blood Advances|April 15, 2024
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemiaRomy E van Weelderen, Christine J Harrison, Kim Klein, et al.
Blood Cancer Discovery|November 12, 2020
Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemiaJuliette Roels, Morgan Thénoz, Bronisława Szarzyńska, et al.
The Journal of Clinical Investigation|February 8, 2021
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemiaFilip Matthijssens, Nitesh D Sharma, Monique Nysus, et al.
Pageof 13